Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer

Journal of Surgical Oncology

Volumn 110, Issue 8, 2014, Pages 935-941

  Ishizuka, Mitsuru ^a   Oyama, Yusuke ^a   Abe, Akihito ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination of platelet count and neutrophil to lymphocyte ratio; Gastric cancer; Inflammation based prognostic system; Neutrophil to lymphocyte ratio; Thrombocytosis

Indexed keywords

ALBUMIN;

AGE; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; FEMALE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; POSTOPERATIVE SURVIVAL; PREDICTION; STOMACH CANCER; SURVIVAL; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS; AGED; BLOOD; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; STOMACH NEOPLASMS;

AGED; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PLATELET COUNT; STOMACH NEOPLASMS;

EID: 84910147126     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23753     Document Type: Article

References (28)

1. McMillan DC: The systemic inflammation-based Glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534-540.
2. Forrest LM, McMillan DC, McArdle CS, et al.: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-1706.
3. Guthrie GJ, Charles KA, Roxburgh CS, et al.: The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-230.
4. Walsh SR, Cook EJ, Goulder F, et al.: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-184.
5. Kwon HC, Kim SH, Oh SY, et al.: Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216-222.
6. Smith RA, Ghaneh P, Sutton R, et al.: Prognosis of resected ampullary adenocarcinoma by preoperative serum CA 19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422-1428.
7. Ishizuka M, Nagata H, Takagi K, et al.: Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol 2012;106:887-891.
8. Hernandez E, Lavine M, Dunton CJ, et al.: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992;69:2975-2977.
9. Guthrie GJ, Roxburgh CS, Horgan PG, et al.: Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 2013;39:89-96.
10. Ishizuka M, Nagata H, Takagi K, et al.: Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109:401-407.
11. Ohsugi Y: Recent advances in immunopathophysiology of interleukin-6: An innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007;30:2001-2006.
12. Shimada H, Takiguchi N, Kainuma O, et al.: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170-176.
13. Ikeda M, Furukawa H, Imamura H, et al.: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287-291.
14. Kochi M, Fujii M, Kanamori N, et al.: Evaluation of serum CEA and CA 19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000;3:177-186.
15. Reiter W, Stieber P, Reuter C, et al.: Multivariate analysis of the prognostic value of CEA and CA 19--9 serum levels in colorectal cancer. Anticancer Res 2000;20:5195-5198.
16. Youden WJ: Index for rating diagnostic tests. Cancer 1950;3:32-35.
17. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112.
18. Moriguchi S, Maehara Y, Korenaga D, et al.: Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992;1:341-346.
19. Siewert JR, Bottcher K, Stein HJ, et al.: Relevant prognostic factors in gastric cancer: Ten--year results of the German gastric cancer study. Ann Surg 1998;228:449-461.
20. Kim JP, Lee JH, Kim SJ, et al.: Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer 1998;1:125-133.
21. Jeong JH, Lim SM, Yun JY, et al.: Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 2012;83:292-299.
22. Roviello F, Marrelli D, de Manzoni G, et al.: Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113-1119.
23. Nguyen KT, Gamblin TC, Geller DA: World review of laparoscopic liver resection - 2,804 patients. Ann Surg 2009;250:831-841.
24. Andre T, Louvet C, Maindrault-Goebel F, et al.: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35: 1343-1347.
25. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11:1477-1483.
26. Hurwitz H, Kabbinavar F: Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005;69:17-24.
27. Aizawa M, Gotohda N, Takahashi S, et al.: Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wallpenetrating gastric cancer. World J Surg 2011;35:2717-2722.
28. Hwang SG, Kim KM, Cheong JH, et al.: Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012;38:562-567.